Courses

Welcome to the Specialized Topics classroom. CME activities are available at no charge to registered users of the site. Not a registered user? Register now for free.

*Note: If you wish to be notified when new courses on specialized topics related to pulmonary hypertension are added, make sure you're logged-in and click "Subscribe" to the left.

To report technical issues, please email PHAOnlineUniv@PHAssociation.org 

Sarcoidosis-Associated Pulmonary Hypertension(SAPH)

Course Image: 
Credit type: 
Physician
Credit Hours: 
1.00
Activity Release Date: 
Mar 28 2012
Activity Expiration Date: 
Oct 31 2013

Vivek N. Iyer, MD, MPH presents this course on Sarcoidosis-Associated Pulmonary Hypertension(SAPH).  This course describes the pathology of sarcoidosis and explains the multifactorial causes that can lead to the development of pulmonary hypertension as an associated disease.  Dr. Iyer also describes the unique etiological and pathological features of SAPH that differ from other types of pulmonary hypertension, as well as the challenges in understanding the epidemiology of SAPH to find a reliable estimate for the prevalence. 

 

Congenital Heart Disease in Pulmonary Arterial Hypertension

Course Image: 
Credit type: 
Physician
Credit Hours: 
1.00
Activity Release Date: 
Feb 3 2012
Activity Expiration Date: 
Oct 31 2013

Dr. Usha Krishnan presents this course which describes the role of pulmonary arterial hypertension in congenital heart disease patients including the management of disease pre and post surgery.  Some of the specific examples of CHD include the identification and treatment options for Eisenmenger Syndrome as well as the role of increased pulmonary resistance in the failing fontan.

Pulmonary Hypertension on the Indian Subcontinent

Course Image: 
Credit type: 
Physician
Credit Hours: 
0.50
Activity Release Date: 
Jan 19 2012
Activity Expiration Date: 
Sep 1 2012

At the 4th International Neonatal and Childhood Pulmonary Vascular Disease Conference, S. Ramakrishnan, MD, DM, AIIMS presented this lecture about the state of pulmonary hypertension in India, a country that has a vastly underdiagnosed population of patients suffering from congenital heart disease.  He discusses how the general barriers to effective health care play out in the field of pulmonary hypertension.

Pulmonary Hypertension Associated with Hemolytic Disorders

Course Image: 
Credit type: 
Physician
Credit Hours: 
0.75
Activity Release Date: 
Jan 19 2012
Activity Expiration Date: 
Sep 1 2012

At the 4th International Neonatal and Childhood Pulmonary Vascular Disease Conferece, Mark Gladwin, MD presented this lecture on the different hemolytic conditions seen in pulmonary hypertension. This includes the way that hemolytic conditions may affect nitric oxide signaling and the impact on survival.

Pulmonary Arterial Hypertension in Systemic Sclerosis: Characteristics and Diagnosis

Course Image: 
Credit type: 
Physician
Credit Hours: 
0.75
Activity Release Date: 
Feb 2 2012
Activity Expiration Date: 
Oct 31 2013

Dr. Silver presents this course which discusses the diagnosis of pulmonary arterial hypertension in systemic sclerosis.  This includes an overview of scleroderma-the classification criteria,predominant subtypes and a look at the causes of PAH in scleroderma patients.

Update on Eisenmenger Syndrome: The Role of Specific Pulmonary Hypertension Therapies

Course Image: 
Credit type: 
Physician
Credit Hours: 
0.50
Activity Release Date: 
Jan 19 2012
Activity Expiration Date: 
Sep 1 2012

Dr. Gary Webb gave this update on Eisenmenger Syndromes and the specific therapies related to pulmonary hypertension at the 4th International Neonatal and Childhood Pulmonary Vascular Disease Conference.  This presentation covers the definition and causes of Eisenmenger syndrome as well as issues involved with pulmonary artery banding.

Emerging Pharmacological Treatment Approaches/Novel Pathways: Strengths, Gaps, Unmet Needs

Course Image: 
Credit type: 
Physician
Credit Hours: 
0.75
Activity Release Date: 
Jan 19 2012
Activity Expiration Date: 
Sep 1 2012

Dr. Robyn Barst discusses the future of pulmonary hypertension therapies in this presentation from the 4th International Neonatal and Childhood Pulmonary Vascular Disease Conference.  From tyrosine kinase inhibitors to inhaled nitrous oxide and the many opportunities for treatment currently under research.

Pulmonary Arteriovenous Malformations After the Bidirectional Glenn and the Role of Vascular Endothelial Growth Factor

Course Image: 
Credit type: 
Physician
Credit Hours: 
0.50
Activity Release Date: 
Oct 5 2011
Activity Expiration Date: 
Sep 1 2012

Narayanswami Sreeram, MD, presented this session on pulmonary arteriovenous malformations after the bidirectional glenn at the 4th International Neonatal and Childhood Pulmonary Vascular Disease Conference.  Dr. Sreeram also discusses the role of vascualr endothelial growth factor.

Inducible Intrapulmonary Arteriovenous Shunt Pathways

Course Image: 
Credit type: 
Physician
Credit Hours: 
0.75
Activity Release Date: 
Oct 5 2011
Activity Expiration Date: 
Sep 1 2012

Marlowe Eldridge, MD presented this session at the 4th International Neonatal and Childhood Pulmonary Vascular Disease Conference.  In this recording Dr. Eldridge discusses how inducible intrapulmonary arteriovenous shunt pathways may challenge conventional wisdom.

Hepatopulmonary Sydrome

Course Image: 
Credit type: 
Physician
Credit Hours: 
0.50
Activity Release Date: 
Oct 5 2011
Activity Expiration Date: 
Sep 1 2012

In this presentation from the 4th International Neonatal and Childhood Pulmonary Vascular Disease Conference, Stephen Archer, MD describes the role for DC68(+) macrophages in the etiology of hepatopulmonary syndrome and how macrophage depletion can cause a reversal. This is especially relevant to pulmonary hypertension as this can transition to portopulmonary hypertension following liver transplantation.

Genetics of Pulmonary Hypertension

Course Image: 
Credit type: 
Physician
Credit Hours: 
0.75
Activity Release Date: 
Oct 5 2011
Activity Expiration Date: 
Sep 1 2012

As part of the preceedings at the 4th Annual International Neonatal and Childhood Pulmonary Vascular Disease Conference, Nicholas Morrell presented this session on the genetic involvement in hereditary pulmonary hypertension.  Dr. Morrell discusses how the expression of the BMPR2 mutation affects the physiological progression of pulmonary hypertension.

Pulmonary Hypertension Associated with Obstructive Lung Disease and Hypoxemia (WHO Group III)

Course Image: 
Credit type: 
Physician
Credit Hours: 
1.00
Activity Release Date: 
Apr 29 2011
Activity Expiration Date: 
Oct 31 2012

Explore the pathophysiology of Pulmonary Hypertension in lung disease as well as the clinical approach to evaluation and treatment of PH patients.

Pulmonary Hypertension in Systemic Sclerosis

Course Image: 
Credit type: 
Physician
Credit Hours: 
1.00
Activity Release Date: 
Jan 27 2011
Activity Expiration Date: 
Oct 31 2013

Dr. Virginia Steen, a Professor of Medicine at Georgetown University specializing in rheumatology, and a member of the PHA
Scientific Leadership Council, presents a talk entitled "Pulmonary Hypertension(PH) in Systemic Sclerosis". We hope that you will enjoy this fascinating presentation by a leader in the field of PH. This course aims to help medical professionals identify the scleroderma patients at a high risk of developing PH, identify the different types of PH that affect scleroderma patients and to understand the PH medications, thier various side effects and when to make changes in the treatment of PH in Scleroderma.

Thoracic Transplantation for Pulmonary Arterial Hypertension

Course Image: 
Credit type: 
Physician
Credit Hours: 
1.00
Activity Release Date: 
Dec 6 2010
Activity Expiration Date: 
Oct 31 2012

This course provides an overview of the current clinical landscape of lung transplantation for patients with pulmonary hypertension.

PHA Online University is a program of the PHA Medical Education Fund. The technical development of this website was made possible through unrestricted medical education grants from Actelion, Gilead, Pfizer and United Therapeutics.